دورية أكاديمية
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols ; Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols
| العنوان: | Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols ; Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols |
|---|---|
| المؤلفون: | Stanulla, M., Schaeffeler, E., Moricke, A., Coulthard, S., Cario, G., Schrauder, A., Kaatsch, P., Dordelmann, M., Welte, K., Zimmerman, M., Reiter, A., Eichelbaum, M., Riehm, H., Schrappe, M., Schwab, M. |
| المصدر: | http://dx.doi.org/10.1182/blood-2008-12-193250Test. |
| بيانات النشر: | Amer Soc Hematology |
| سنة النشر: | 2009 |
| المجموعة: | The University of Adelaide: Digital Library |
| مصطلحات موضوعية: | Humans, Brain Neoplasms, Neoplasms, Second Primary, Vincristine, Daunorubicin, Prednisone, Asparaginase, Methyltransferases, Antineoplastic Combined Chemotherapy Protocols, Risk Factors, Follow-Up Studies, Heterozygote, Homozygote, Child, Preschool, Infant, Germany, Female, Male, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| الوصف: | Thiopurine methyltransferase (TPMT)is involved in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine. TPMT activity is significantly altered by genetics, and heterozygous and even more homozygous variant people reveal substiantially decreased TPMT activity. Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs. Importantly, childhood ALL patients with low TPMT activity have been considered to be at increased risk of developing therapy-associated acute myeloid leukemia and brain tumors. In the present study, we genotyped 105 of 129 patients who developed a secondary malignant neoplasm after ALL treatment on 7 consecutive German Berlin-Frankfurt-Münster trials for all functionally relevant TPMT variants. Frequencies of TPMT variants were similarly distributed in secondary malignant neoplasm patients and the overall ALL patient population of 814 patients. Thus, TPMT does not play a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, according to Berlin-Frankfurt-Münster strategies. ; Martin Stanulla, Elke Schaeffeler, Anja Möricke, Sally A. Coulthard, Gunnar Cario, André Schrauder, Peter Kaatsch, Michael Dördelmann, Karl Welte, Martin Zimmermann, Alfred Reiter, Michel Eichelbaum, Hansjörg Riehm, Martin Schrappe, and Matthias Schwab |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0006-4971 1528-0020 |
| العلاقة: | Blood, 2009; 114(7):1314-1318; http://hdl.handle.net/2440/58900Test |
| DOI: | 10.1182/blood-2008-12-193250 |
| الإتاحة: | https://doi.org/10.1182/blood-2008-12-193250Test http://hdl.handle.net/2440/58900Test |
| حقوق: | © 2009 by The American Society of Hematology |
| رقم الانضمام: | edsbas.A47D4EA3 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2008-12-193250 |